company background image
LQDA logo

Liquidia NasdaqCM:LQDA Stock Report

Last Price

US$13.81

Market Cap

US$1.0b

7D

-9.9%

1Y

103.7%

Updated

18 Apr, 2024

Data

Company Financials +

Liquidia Corporation

NasdaqCM:LQDA Stock Report

Market Cap: US$1.0b

LQDA Stock Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

LQDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Liquidia Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Liquidia
Historical stock prices
Current Share PriceUS$13.81
52 Week HighUS$16.99
52 Week LowUS$5.71
Beta0.19
1 Month Change-13.82%
3 Month Change7.14%
1 Year Change103.69%
3 Year Change398.56%
5 Year Change49.14%
Change since IPO24.41%

Recent News & Updates

Recent updates

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Jan 19
Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Dec 20
Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Aug 17
Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

Mar 18
Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Feb 06
Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 25
Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Liquidia: United Manages A Temporary Win

Sep 12

Liquidia tumbles 33% after judge denies stay request in United Therapeutics patent dispute

Aug 30

Liquidia  Q2 2022 Earnings Preview

Aug 10

Liquidia Vs. MannKind: Treprostinil Is The Big 'IF'

Jun 29

Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets

May 15
Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Mar 16
Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Liquidia And United: The Tango Continues

Jan 18

Shareholder Returns

LQDAUS PharmaceuticalsUS Market
7D-9.9%-2.3%-3.7%
1Y103.7%11.4%20.2%

Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.

Return vs Market: LQDA exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is LQDA's price volatile compared to industry and market?
LQDA volatility
LQDA Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: LQDA has not had significant price volatility in the past 3 months.

Volatility Over Time: LQDA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004145Roger Jeffswww.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.

Liquidia Corporation Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LQDA fundamental statistics
Market capUS$1.05b
Earnings (TTM)-US$78.50m
Revenue (TTM)US$17.49m

60.0x

P/S Ratio

-13.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LQDA income statement (TTM)
RevenueUS$17.49m
Cost of RevenueUS$2.89m
Gross ProfitUS$14.60m
Other ExpensesUS$93.10m
Earnings-US$78.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin83.49%
Net Profit Margin-448.89%
Debt/Equity Ratio97.3%

How did LQDA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.